Avacta Group plc
("Avacta" or the "Company")
Avacta to Present the pre|CISION® Dual Payload Candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium
LONDON and PHILADELPHIA – November 4, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces it will present AVA6207, its Next-Generation pre|CISION® dual payload peptide-drug conjugate (PDC), in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20.
AVA6207 uses the Company’s pre|CISION® PDC technology to deliver two synergistic payloads directly to tumor cells in a single molecule, combining two complementary mechanisms to combat highly resistant cancers. This dual payload molecule functions by inhibiting topoisomerase I (TOP1), inducing severe DNA damage, while simultaneously inhibiting Ataxia Telangiectasia and Rad3-related (ATR) kinase through an ATR inhibitor (ATRi), thus blocking the DNA damage response to prevent cancer cells from repairing TOP1 inhibitor (TOP1i)-induced damage. Combining these two payloads into one pre|CISION® PDC that delivers them directly to the tumor has tremendous potential to improve outcomes in TOP1i-resistant cancers, a growing area of unmet need in oncology.
Details of the poster presentation
Title: AVA6207 is a novel pre|CISION® technology compound delivering complementary TOP1i and ATRi payloads to the tumor microenvironment following FAP cleavage
Authors: Victoria Juskaite, Tom Clough, Ellen Watts, et al. and David Jones
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Session Date and Time: Thursday, November 19, 09:00-17:30
Location: Exhibition Hall, Poster Area
Abstract Number: 161
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Christina Coughlin, Chief Executive Officer |
via Cohesion Bureau |
|
|
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance |
||
|
Zeus (Broker) James Hornigold / George Duxberry (Investment Banking) |
||
|
Cohesion Bureau Communications / Media / Investors Chris Maggos |
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.
Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.
About FAP-Exd (AVA6103)
AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.